Table 1.
Baseline characteristics of the study group (n = 42).
| Characteristics | No. (%) |
|---|---|
| Median Age (range), y | 64 (41–78) |
| Sex | 26M/16F |
| Smoking history | |
| Former or current | 42 (100) |
| FEV1 (mean % predicted ± SD) | 78.64 ± 14.32 |
| FVC (mean % predicted ± SD) | 81.58 ± 15.58 |
| DLCO (mean % ± SD) | 79.42 ± 14.86 |
| Histology (%) | |
| Adenocarcinoma | 33 (78.5) |
| Squamous cell carcinoma | 5 (11.9) |
| Adenosquamous | 2 (4.8) |
| Sarcomatoid | 2 (4.8) |
| Clinical stage before TKIs/ICIs | |
| IIIA | 11 (26.1) |
| T1cN2 | 2 (4.8) |
| T2aN2 | 2 (4.8) |
| T2bN2 | 3 (7.0) |
| T4N0 | 4 (9.5) |
| IIIB | 10 (23.8) |
| T3N2 | 8 (19.0) |
| T4N2 | 2 (4.8) |
| IIIC | 5 (12.0) |
| T1bN3 | 1 (2.4) |
| T1cN3 | 1 (2.4) |
| T3N3 | 2 (4.8) |
| T4N3 | 1 (2.4) |
| IV | 16 (38.1) |
| IVa | 14 (33.3) |
| IVb | 2 (4.8) |
| Drug regimen | |
| TKIs | 23 (54.9) |
| Gefitinib | 5 (12.0) |
| Erlotinib | 4 (9.5) |
| Afatinib | 6 (14.2) |
| Osimertinib | 5 (12.0) |
| Crizotinib | 2 (4.8) |
| Alectinib | 1 (2.4) |
| ICIs | 19 (45.1) |
| Pembrolizumab | 14 (33.3) |
| Nivolumab | 3 (7.0) |
| Atezolizumab | 2 (4.8) |
| Months from start therapy and surgery (median, range) | 15 (6–23) |
FEV1 = forced expiratory volume in 1 s; SD = Standard Deviation; FVC = forced vital capacity; DLCO = carbon monoxide lung diffusion capacity; TKIs = tyrosine kinase inhibitors; ICIs = immune checkpoint inhibitors.